One may therefore consider the development of carrier-based B cell epitope-containing vaccines by combining peptides derived from the IgE binding sites of the respiratory allergens and the corresponding cross-reactive class II food allergens to obtain combination vaccines for treatment of pollen allergy and the associated oral allergy syndrome (Figure 4, lower, right). The gene discussed is IGHE; the disease is seasonal allergic rhinitis.